KR102296416B1 - 항-세라마이드 항체 - Google Patents

항-세라마이드 항체 Download PDF

Info

Publication number
KR102296416B1
KR102296416B1 KR1020177006255A KR20177006255A KR102296416B1 KR 102296416 B1 KR102296416 B1 KR 102296416B1 KR 1020177006255 A KR1020177006255 A KR 1020177006255A KR 20177006255 A KR20177006255 A KR 20177006255A KR 102296416 B1 KR102296416 B1 KR 102296416B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
antigen
thr
variable region
Prior art date
Application number
KR1020177006255A
Other languages
English (en)
Korean (ko)
Other versions
KR20170066327A (ko
Inventor
지미 로톨로
리차드 콜레스닉
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
세라미드 테라퓨틱스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터, 세라미드 테라퓨틱스 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Publication of KR20170066327A publication Critical patent/KR20170066327A/ko
Application granted granted Critical
Publication of KR102296416B1 publication Critical patent/KR102296416B1/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020177006255A 2014-08-07 2015-08-07 항-세라마이드 항체 KR102296416B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462034453P 2014-08-07 2014-08-07
US62/034,453 2014-08-07
PCT/US2015/044144 WO2016022883A1 (en) 2014-08-07 2015-08-07 Anti-ceramide antibodies

Publications (2)

Publication Number Publication Date
KR20170066327A KR20170066327A (ko) 2017-06-14
KR102296416B1 true KR102296416B1 (ko) 2021-09-01

Family

ID=55264608

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177006255A KR102296416B1 (ko) 2014-08-07 2015-08-07 항-세라마이드 항체

Country Status (14)

Country Link
US (3) US10450385B2 (zh)
EP (1) EP3177650A4 (zh)
JP (1) JP6670297B2 (zh)
KR (1) KR102296416B1 (zh)
CN (1) CN107074949B (zh)
AU (1) AU2015300902B2 (zh)
BR (1) BR112017002433A2 (zh)
CA (1) CA2957415C (zh)
IL (1) IL250374B (zh)
MX (1) MX2017001686A (zh)
NZ (1) NZ728981A (zh)
RU (1) RU2717651C2 (zh)
SG (1) SG11201700787XA (zh)
WO (1) WO2016022883A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102588359B1 (ko) 2016-03-04 2023-10-13 제이엔 바이오사이언시즈 엘엘씨 Tigit에 대한 항체
US11634486B2 (en) 2016-12-23 2023-04-25 Bluefin Biomedicine, Inc. Anti-SEZ6L2 antibodies and antibody drug conjugates
WO2020231629A1 (en) 2019-05-16 2020-11-19 Snake River Bioscience, Inc. Compositions and methods for the treatment of major depressive disorder
AU2020289179B2 (en) * 2019-06-06 2024-05-02 Jacobio Pharmaceuticals Co., Ltd. Binding molecule specific for CD73 and use of binding molecule
US10975169B1 (en) 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
KR102245082B1 (ko) * 2020-02-14 2021-04-26 단국대학교 천안캠퍼스 산학협력단 치주인대전구세포 표면에 특이적으로 결합하는 두 가지 IgG 타입 단일클론항체 LG43, LG73 및 그의 용도
JP2023534779A (ja) * 2020-03-18 2023-08-14 メモリアル スローン ケタリング キャンサー センター 抗セラミド抗体
IL298111A (en) 2020-06-02 2023-01-01 Arcus Biosciences Inc Antibodies to tigit

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02128697A (ja) * 1988-11-09 1990-05-17 Hoechst Japan Ltd 抗フコシルセラミドモノクローナル抗体
US7897753B2 (en) * 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
RU2310393C1 (ru) * 2006-02-16 2007-11-20 ФГУ Научно-исследовательский институт по изучению лепры Федерального агентства по здравоохранению и социальному развитию Российской Федерации Способ прогнозирования обострений лепрозных невропатий у больных лепрой
AU2008247368B2 (en) * 2007-05-06 2013-10-10 Sloan Kettering Institute For Cancer Research Methods for treating and preventing GI syndrome and Graft versus Host disease
US9163091B2 (en) 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
US8410251B2 (en) * 2008-06-20 2013-04-02 National University Corporation Okayama University Antibody against calcified globule and use of the same
KR101050829B1 (ko) 2008-10-02 2011-07-20 서울대학교산학협력단 항 pd-1 항체 또는 항 pd-l1 항체를 포함하는 항암제
EP2419447B1 (en) * 2009-04-17 2017-08-23 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
FR2971250A1 (fr) * 2011-02-07 2012-08-10 Univ Nantes Anticorps anti-gb3 utiles dans le traitement des maladies associees a l'angiogenese
ES2643241T3 (es) * 2012-02-21 2017-11-21 Toray Industries, Inc. Composición medicinal para tratar y/o prevenir el cáncer
EP3903820A1 (en) * 2012-05-25 2021-11-03 Sloan-Kettering Institute for Cancer Research An anti-ceramide antibodies
JP2023534779A (ja) 2020-03-18 2023-08-14 メモリアル スローン ケタリング キャンサー センター 抗セラミド抗体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CS Hampe et el., Exp Clin Endocrinol Diabets, 2005, 113(7) 381-387.
Soma Rohathi et al., The Journal of Immunology, 2012, 189(12) 5820-5830.

Also Published As

Publication number Publication date
US20190389970A1 (en) 2019-12-26
NZ728981A (en) 2024-03-22
RU2017105596A (ru) 2018-09-07
EP3177650A4 (en) 2018-01-03
KR20170066327A (ko) 2017-06-14
US10450385B2 (en) 2019-10-22
US11447572B2 (en) 2022-09-20
BR112017002433A2 (pt) 2017-11-28
AU2015300902A1 (en) 2017-03-02
US20170335014A1 (en) 2017-11-23
AU2015300902B2 (en) 2020-05-28
EP3177650A1 (en) 2017-06-14
CN107074949B (zh) 2021-06-15
SG11201700787XA (en) 2017-02-27
RU2017105596A3 (zh) 2019-04-17
IL250374A0 (en) 2017-03-30
IL250374B (en) 2021-04-29
RU2717651C2 (ru) 2020-03-24
CA2957415A1 (en) 2016-02-11
WO2016022883A1 (en) 2016-02-11
JP2017527544A (ja) 2017-09-21
MX2017001686A (es) 2017-09-01
US20230416409A1 (en) 2023-12-28
CN107074949A (zh) 2017-08-18
CA2957415C (en) 2021-07-13
JP6670297B2 (ja) 2020-03-18

Similar Documents

Publication Publication Date Title
KR102296416B1 (ko) 항-세라마이드 항체
US10273306B2 (en) Antibodies directed against ICOS for treating graft-versus-host disease
EP3858856A1 (en) Anti-b7-h3 monoclonal antibody and use thereof in cell therapy
KR101537840B1 (ko) 항-인간 cd52 면역글루불린
EA015009B1 (ru) АНТИГЕНСВЯЗЫВАЮЩИЕ МОЛЕКУЛЫ, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
KR20140006096A (ko) Masp-2 의존적 보체 활성화를 억제하는 조성물
CN106061999B (zh) Il-21抗体
JP2012513761A (ja) 初期の眼内リンパ腫の治療に対する抗cd20抗体の使用方法
US20230203178A1 (en) Chimeric antigen receptor car or car construct targeting bcma and cd19 and application thereof
CA2404340C (en) Methods of blocking tissue destruction by autoreactive t cells
WO2023001155A1 (zh) 一种磷脂酰肌醇蛋白聚糖3抗体及其应用
EP4209512A1 (en) Development of drug therapeutic agent containing adaptor and use thereof
TWI819352B (zh) 包含il-12及抗fap抗體的融合蛋白及其用途
WO2023246574A1 (zh) 靶向gpc3的抗体及其用途
KR20230054451A (ko) 길항작용 cd40 모노클로날 항체를 사용하여 자가면역 질환을 치료하는 방법
AU2022281461A1 (en) C-x-c motif chemokine receptor 6 (cxcr6) binding molecules, and methods of using the same
AU2022225026A1 (en) Preparation of siglec-15 binding protein and use thereof

Legal Events

Date Code Title Description
A201 Request for examination
A302 Request for accelerated examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant